Alejandro González Veliz: Does Elevated Lp(a) Always Mean the Same Cardiovascular Risk?
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn about recent article by Niekbachsh Mohammadnia et al., published in JAMA Cardiology, adding:
“Does elevated Lp(a) always mean the same cardiovascular risk?
This new JAMA Cardiology study suggests the answer is no.
Among more than 43,000 individuals followed for over 13 years, IL-6 emerged as the only inflammatory biomarker that significantly modified the association between elevated Lp(a) and incident coronary artery disease.
Patients with both high Lp(a) and high IL-6 had substantially greater coronary risk, whereas elevated Lp(a) alone carried much less excess risk when IL-6 levels were low.
Interestingly, this interaction was not observed for aortic stenosis, suggesting different biological mechanisms despite Lp(a) being a shared risk factor.
These findings reinforce the concept that cardiovascular prevention may increasingly rely on combining lipid biology with inflammatory profiling, potentially helping identify those who could derive the greatest benefit from emerging Lp(a)-lowering and anti-inflammatory therapies.
What do you think will become the next essential biomarker in preventive cardiology: IL-6, hsCRP, or something else?”
Title: Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis
Authors: Niekbachsh Mohammadnia, Linke Li, Daniel Ezzat, Zhi Yu, Vineet K. Raghu, Jennifer L. Halford, Niels P. Riksen, Pradeep Natarajan, Jan H. Cornel, Michael C. Honigberg, Saloua El Messaoudi
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation
-
Aug 21, 2026, 09:07Sujal Lohana: Building a Better Blood Donor–Seeker App
-
Aug 21, 2026, 08:55Robert Sidonio: Connecting Experts in Bleeding and Clotting Disorders